1. Home
  2. STTK vs AGFY Comparison

STTK vs AGFY Comparison

Compare STTK & AGFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • AGFY
  • Stock Information
  • Founded
  • STTK 2016
  • AGFY 2016
  • Country
  • STTK United States
  • AGFY United States
  • Employees
  • STTK 44
  • AGFY N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • AGFY Military/Government/Technical
  • Sector
  • STTK Health Care
  • AGFY Consumer Discretionary
  • Exchange
  • STTK Nasdaq
  • AGFY Nasdaq
  • Market Cap
  • STTK 48.9M
  • AGFY 41.3M
  • IPO Year
  • STTK 2020
  • AGFY 2021
  • Fundamental
  • Price
  • STTK $1.02
  • AGFY $28.74
  • Analyst Decision
  • STTK Hold
  • AGFY
  • Analyst Count
  • STTK 5
  • AGFY 0
  • Target Price
  • STTK $2.00
  • AGFY N/A
  • AVG Volume (30 Days)
  • STTK 5.2M
  • AGFY 13.4K
  • Earning Date
  • STTK 08-14-2025
  • AGFY 08-08-2025
  • Dividend Yield
  • STTK N/A
  • AGFY N/A
  • EPS Growth
  • STTK N/A
  • AGFY N/A
  • EPS
  • STTK N/A
  • AGFY N/A
  • Revenue
  • STTK $2,997,000.00
  • AGFY $12,260,000.00
  • Revenue This Year
  • STTK N/A
  • AGFY N/A
  • Revenue Next Year
  • STTK N/A
  • AGFY N/A
  • P/E Ratio
  • STTK N/A
  • AGFY N/A
  • Revenue Growth
  • STTK N/A
  • AGFY 186.99
  • 52 Week Low
  • STTK $0.69
  • AGFY $2.71
  • 52 Week High
  • STTK $3.95
  • AGFY $84.44
  • Technical
  • Relative Strength Index (RSI)
  • STTK 61.64
  • AGFY 56.08
  • Support Level
  • STTK $0.71
  • AGFY $27.78
  • Resistance Level
  • STTK $1.05
  • AGFY $33.75
  • Average True Range (ATR)
  • STTK 0.09
  • AGFY 2.52
  • MACD
  • STTK 0.03
  • AGFY 0.22
  • Stochastic Oscillator
  • STTK 69.18
  • AGFY 40.93

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About AGFY Agrify Corporation

Agrify Corp is a developer of branded inventive solutions for the cannabis and hemp industries. Its Senorita brand offers consumers hemp-derived tetrahydrocannabinol (THC) beverages that mirror cocktails like a margarita - in three flavors - classic Lime Jalapeno Margarita, Mango Margarita, and Paloma. In addition to beverages, Agrify has also historically been a provider of inventive cultivation and extraction solutions for the cannabis industry. Its comprehensive extraction product line, which includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates.

Share on Social Networks: